All L1CAM reagents are produced in house and quality controlled, including 12 L1CAM Antibody, 2 L1CAM ELISA, 25 L1CAM Gene, 1 L1CAM Lysate, 1 L1CAM Protein, 2 L1CAM qPCR. All L1CAM reagents are ready to use.
Recombinant L1CAM proteins are expressed by HEK293 Cells with fusion tags as C-human IgG1-Fc & His, C-His.
L1CAMantibodies are validated with different applications, which are ELISA, ICC/IF, IF, FCM, ELISA(Cap), IHC-P, ELISA(Det).
L1CAMcDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each L1CAM of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
L1CAMELISA Kit are quality controlled by 8 internation QC standard which guarantee every ELISA Kit with high quality.
L1 cell adhesion molecule (L1CAM), also designated as CD171, is a cell adhesion receptor of the immunoglobulin superfamily, known for its roles in nerve cell function. While originally believed to be present only in brain cells, in recent years L1-CAM has been detected in other tissues, and in a variety of cancer cells, including some common types of human cancer. L1CAM interacts with a variety of ligands including axonin-1, CD9, neurocan and intergrins, and it has been revealed that the RGD motif in the sixth Ig domain of L1CAM is a binding site for integrins, thus important for nuclear signaling. Disruption of L1CAM function causes three X-linked neurological syndromes, i.e. hydrocephalus, MASA syndrome (mental retardation, aphasia, shuffling gait and adducted thumbs) and spastic paraplegia syndrome. Overexpression of L1CAM in normal and cancer cells increased motility, enhanced growth rate and promoted cell transformation and tumorigenicity. Recent work has identified L1CAM (CD171) as a novel marker for human carcinoma progression, and a candidate for anti-cancer therapy.